Tirzepatide 10mg

Tirzepatide is a modified-chain synthetic peptide representing the first dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Its approximate molecular weight is 4,813 Da, with a 5-day half-life documented in the literature.

Molecular design:

• Human GLP-1 derived basic scaffold
• 39 amino acids with strategic modifications for dual receptor activity
• C20 acyl chain conjugated at specific position to extend half-life
• Serum albumin binding greater than 98%, which protects against enzymatic degradation

The compound exhibits slightly unbalanced affinity toward GIP, a feature that appears responsible for the superior response versus pure GLP-1 agonists such as Semaglutide. The SURPASS-1 through SURPASS-5 phase 3 trials established its reference pharmacological profile.

Tirzepatide simultaneously activates two incretin pathways that normally operate in a coordinated manner in post-prandial physiology:

GLP-1 Pathway:

• Increases glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon secretion from alpha cells
• Delays gastric emptying, prolonging post-meal satiety
• Acts on hypothalamic nuclei (arcuate, paraventricular) modulating appetite

GIP Pathway:

• Potentiates GLP-1-induced insulin secretion
• Modulates lipid metabolism in adipose tissue
• Improves nutrient partitioning toward oxidation vs storage
• Reduces low-grade inflammation in visceral adipose tissue

The combination produces a documented synergistic effect: simultaneous activation of both receptors generates a greater metabolic response than the sum of each component separately, especially in terms of fat mass loss with relative preservation of lean mass.

The compound is widely investigated in the following contexts:

• Obesity Research: SURMOUNT-1 through SURMOUNT-4 reported an average reduction in body weight of 15 to 22% at 72 weeks with doses of 10 to 15 mg/week
• Type 2 diabetes SURPASS-1 to SURPASS-5 established HbA1c reductions greater than those observed with Semaglutide
• Fatty liver disease Phase 2 trials show significant reduction in liver lipid content
• Hypertension associated with obesity: average reductions of 6 to 8 mmHg in systolic pressure
• Sleep apnea: SURMOUNT-OSA showed improvement in the apnea-hypopnea index
• Cardiovascular Research: SURPASS-CVOT ongoing evaluating major outcomes

Reconstitution:

Add 2 ml of bacteriostatic water to the 10 mg vial, letting the liquid slowly run down the inner wall of the vial. Homogenize with a gentle rotating motion, without shaking. Store refrigerated between 2 and 8°C.

Resulting concentration: 5,000 mcg/ml or 5 mg/ml.

A 10-mg vial provides 10 mg of the compound for research preparations at the specified concentration.

Adverse events commonly reported in clinical trial literature:

• Gastrointestinal: nausea (20-30%), diarrhea, constipation, dyspepsia
• Decreased appetite

Less common but relevant events reported in the literature: acute pancreatitis (rare), hypersensitivity reactions, cholelithiasis associated with rapid weight loss.

Documented contraindications in clinical literature:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia Type 2 (MEN 2) Syndrome
• Active pancreatitis or history of severe pancreatitis
• Pregnancy and breastfeeding

Relevant documented drug interactions: delayed gastric emptying may alter the absorption of oral contraceptives and other gastric rate-sensitive drugs.

Tirzepatide is frequently studied alongside other compounds in research protocols depending on the study objective:

• Body recomposition Tirzepatide + CJC No DAC + Ipamorelin, investigated for its association with lean mass preservation during fat loss
• Fatty liver disease Tirzepatide + MOTS-C, studied for its association with mitochondrial lipid oxidation
• Metabolic Syndrome Tirzepatide + Semaglutide in crossover studies (not simultaneous)
• Leather support Tirzepatide + GHK-Cu, investigated in contexts of skin laxity associated with weight loss
• Pre-operative optimization Low-dose tirzepatide in pre-bariatric optimization research

1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
4. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
5. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.

Product intended for scientific research purposes only. Not for human use or direct consumption. The buyer assumes full responsibility for handling the compound.